<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>503-TAMSULOSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMSULOSINE" rxcui="77492">
<ATC code="G04CA02" />
<ATC code="G04CA52" />
<ATC code="G04CA53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use </SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>503-TAMSULOSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMSULOSINE" rxcui="77492">
<ATC code="G04CA02" />
<ATC code="G04CA52" />
<ATC code="G04CA53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>503-TAMSULOSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMSULOSINE" rxcui="77492">
<ATC code="G04CA02" />
<ATC code="G04CA52" />
<ATC code="G04CA53" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>503-TAMSULOSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMSULOSINE" rxcui="77492">
<ATC code="G04CA02" />
<ATC code="G04CA52" />
<ATC code="G04CA53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
<ATC code="C08DA51" />
<ATC code="C09BB10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires. </COMMENT>
</INTERACTION>
</INTERACTIONS>
